| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.28 MB | Adobe PDF |
Authors
Abstract(s)
O envolvimento da nanotecnologia na medicina abriu novos horizontes de possibilidades terapêuticas. Em particular, um dos exemplos é o uso da nanotecnologia para melhorar e/ou desenvolver novos tratamentos para o cancro. Neste contesto, as abordagens baseadas em imunoterapia junto à nanotecnologia surgiram como uma solução promissora que poderia mudar o paradigma do cancro. A imunoterapia emprega diversas estratégias no combate do cancro, tais como anticorpos monoclonais, check point inibidores, citocinas, imunoterapia baseada em células e vacinas terapêuticas. As nanovacinas são um produto da junção das vacinas convencionais com a nanotecnologia. No contesto deste trabalho, são avaliadas as propriedades toxicológicas e imunoestimulate das Passion Fruits-Like Nanopartículas, com o intuito de serem utilizadas posteriormente como nanotransportadores no desenvolvimento de vacina. Neste trabalho verificou-se que as pfNPs eram não tóxicas após 48h incubadas com nanopartículas de concentrações até 100 µg/mL para os macrófagos RAW 264.7 e KG-1, bem como concentrações até 10 µg/mL para as células BDCM. As pfNPs foram altamente capturadas pelas células RAW 264.7, enquanto que a captação pelas células KG-1 foi limitada. As propriedades imunoestimuladoras das pfNPs foram avaliadas apenas numa linhagem celular, RAW 264.7, mostrando um aumento estatisticamente significativo da expressão dos receptores CD80 e CD86 às 48h. Esses achados sugerem que as pfNPs têm uma aplicação potencial como nanovacinas na imunoterapia contra o cancro.
The use of nanotechnology in medicine has expanded horizons of the therapeutic possibilities. One example is the use of nanotechnology for improving and developing new cancer treatments. Immunotherapy-based approaches with nanotechnology have emerged as a promising solution that could change cancer paradigm. Cancer immunotherapy employs different strategies to fight against cancer, such as monoclonal antibodies, immune checkpoint inhibitors, cytokines, cell-based immunotherapy and cancer vaccines. Nanovaccines are a product of the meeting between conventional vaccines and nanotechnology. In this work, passion fruits-like nanoparticles are evaluated for their toxicity and immunostimulation properties, in order to be further developed as a vaccine nanocarrier. The results suggest that pfNPs were nontoxic at 48 h up to 100 µg/mL for RAW 264.7 and KG-1 macrophages, as well as up to 10 µg/mL for BDCM cells. The pfNPs were highly uptaken by RAW 264.7, while their uptake was limited in KG-1 cells. The immunostimulatory properties of pfNPs were evaluated only in RAW 264.7 cells and showed a statistically significant increased expression of CD80 and CD86 receptors at 48h. These findings suggest that the pfNPs have a potential application as nanovaccines in cancer immunotherapy.
The use of nanotechnology in medicine has expanded horizons of the therapeutic possibilities. One example is the use of nanotechnology for improving and developing new cancer treatments. Immunotherapy-based approaches with nanotechnology have emerged as a promising solution that could change cancer paradigm. Cancer immunotherapy employs different strategies to fight against cancer, such as monoclonal antibodies, immune checkpoint inhibitors, cytokines, cell-based immunotherapy and cancer vaccines. Nanovaccines are a product of the meeting between conventional vaccines and nanotechnology. In this work, passion fruits-like nanoparticles are evaluated for their toxicity and immunostimulation properties, in order to be further developed as a vaccine nanocarrier. The results suggest that pfNPs were nontoxic at 48 h up to 100 µg/mL for RAW 264.7 and KG-1 macrophages, as well as up to 10 µg/mL for BDCM cells. The pfNPs were highly uptaken by RAW 264.7, while their uptake was limited in KG-1 cells. The immunostimulatory properties of pfNPs were evaluated only in RAW 264.7 cells and showed a statistically significant increased expression of CD80 and CD86 receptors at 48h. These findings suggest that the pfNPs have a potential application as nanovaccines in cancer immunotherapy.
Description
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2019
Keywords
Cancer immunotherapy, Nanovaccines, Passion fruits-like nanoparticles. Mestrado Integrado - 2019